Endophthalmitis after anti-VEGF injections.
Klein
Kathryn S
KS
Walsh
Mark K
MK
Hassan
Tarek S
TS
Halperin
Lawrence S
LS
Castellarin
Alessandro A
AA
Roth
Daniel
D
Driscoll
Sarah
S
Prenner
Jonathan L
JL
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000009:adverse effects; D000068258:Bevacizumab; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D009877:Endophthalmitis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy; D000069579:Ranibizumab; D012307:Risk Factors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab